By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Wealth Beat NewsWealth Beat News
  • Home
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Notification Show More
Aa
Wealth Beat NewsWealth Beat News
Aa
  • News
  • Finance
  • Investing
  • Banks
  • Mortgage
  • Loans
  • Credit Cards
  • Small Business
  • Dept Management
Follow US
Wealth Beat News > News > Natura Takes A Bath To Pass On Body Shop Stink
News

Natura Takes A Bath To Pass On Body Shop Stink

News
Last updated: 2023/11/16 at 8:39 AM
By News
Share
4 Min Read
SHARE

By Breakingviews

Natura’s (NTCO) discounted sale of The Body Shop may help breathe new life into the eco-friendly brand. Six years after snapping it up from L’Oréal (OTCPK:LRLCF, OTCPK:LRLCY) for $1.1 billion, the $4 billion Brazilian cosmetics giant has agreed to sell the struggling maker of shower gels and body balms to private equity group Aurelius (OTCPK:AURQF, AUL:CA) for 207 million pounds ($258 million). The nearly 80% discount to the original price tag reflects the brand’s fading relevance. Buyer Aurelius will need to apply a lot of polish to fetch a pretty penny.

Tuesday’s sale announcement caps off a months-long search for a buyer. Unlike successful luxury lotion maker Aesop, which Natura sold in April for $2.5 billion, The Body Shop has been languishing: Net revenue shrank 15% in the first nine months of 2023 from the year prior, and profit margins are below the industry average. To get rid of the brand, Natura boss Fábio Barbosa had to sell it for a song. Assuming The Body Shop can deliver an adjusted EBITDA margin of 7.7%, same as in the last quarter, on annualized revenue of $680 million, its EBITDA would amount to $52 million. Its sale price, which includes 90 million pounds in conditional payments, is less than 5 times that sum. Sector leader L’Oréal and Estée Lauder (EL) trade at multiples of between 18 and 21 times.

The discounted price gives a whiff of distress, but in passing the buck Barbosa can finally focus on turning around the rest of his company. Aurelius, on the other hand, faces a daunting challenge in trying to revive a jaded brand. But there are ways for the deal math to stack up. If Aurelius were able to help The Body Shop increase its revenue by 6.5% a year for five years, the mid-point of expected average growth at L’Oréal and Estée Lauder, and double its potential EBITDA margin to 15% – still below-average versus sector peers – its private equity owner would be able to generate an internal rate of return of just above 30%, Breakingviews calculations show. That assumes Aurelius funds the deal with some $100 million of debt, twice expected EBITDA this year, and uses cash flow to fund investments.

These are bold assumptions. Deal volume for global cosmetics M&A has increased over 500% to $50 billion in the year to October from $7.8 billion in 2022, according to Dealogic data, reflecting growing investor appetite for the segment. Yet improving The Body Shop’s appeal by, for instance, changing its concept and expanding its presence in beauty-focused Asia is not guaranteed success. For The Body Shop, a full makeover is still risky, even when it comes this cheap.

Context News

Brazilian cosmetics giant Natura & Co said on Nov. 14 that it had reached an agreement to sell struggling eco-friendly retailer The Body Shop to private equity group Aurelius for an enterprise value of 207 million pounds ($258 million). The price includes an earn-out payment of 90 million pounds payable in up to five years after closing. The transaction is expected to close by Dec. 31. Shares in Natura were up 3.6% at 1545 GMT on November 15, 2023.

Original Post

Editor’s Note: The summary bullets for this article were chosen by Seeking Alpha editors.

Read the full article here

News November 16, 2023 November 16, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Fast Four Quiz: Precision Medicine in Cancer

How much do you know about precision medicine in cancer? Test your knowledge with this quick quiz.
Get Started
Excelerate Energy: Nearby Best Energy-Source Cap-Gain Prospect (NYSE:EE)

The primary focus of this article is Excelerate Energy, Inc. (NYSE:EE). Investment…

Penske Is Steady, But The Road Ahead May Be Bumpy (NYSE:PAG)

Investing Thesis On Wednesday, Penske Automotive Group (NYSE:PAG) released a superficially encouraging…

Top Financial – No, Stop It, This Is Silly (NASDAQ:TOP)

TOP Financial Moves, yes, but why? TOP Financial (NASDAQ:TOP) was quite the…

You Might Also Like

News

Investors Keep Eye On Fed Decision While Adobe, Broadcom Set To Report Earnings

By News
News

My Portfolio Strategy For 2026

By News
News

Orla Mining Stock: A Consistent Per Share Grower At A Reasonable Price (NYSE:ORLA)

By News
News

Trinity Capital Stock: Why I Put 25% Of My Portfolio Into This BDC (NASDAQ:TRIN)

By News
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Contact US
More Info
  • Newsletter
  • Finance
  • Investing
  • Small Business
  • Dept Management

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions

Join Community

2025 © wealthbeatnews.com. All Rights Reserved.

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts etc.

I have read and agree to the terms & conditions
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Lost your password?